STOCK TITAN
  1. Home
  2. News
  3. VERA

Vera Therapeutics, Inc. - $VERA STOCK NEWS

Welcome to our dedicated page for Vera Therapeutics news (Ticker: $VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vera Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vera Therapeutics's position in the market.

News
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary

Vera Therapeutics, Inc. (Nasdaq: VERA) granted inducement awards to new employees under its 2024 Inducement Plan. The awards include non-qualified stock options and restricted stock units. The stock options have exercise prices based on Vera's closing trading prices on specific dates. The awards vest over four years, contingent on the employees' continued service with the company. These awards were approved as inducements under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
Rhea-AI Summary
Vera Therapeutics, Inc. announces the acceptance of 72-week data of atacicept in IgAN as a best-ranked abstract and the analysis of the impact of atacicept on hematuria in IgAN as a focused oral presentation at the 61st European Renal Association Congress. The Phase 2b ORIGIN clinical trial data will be presented virtually and in Stockholm from May 23—26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
-
News
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Vera Therapeutics, Inc. (VERA) presented positive 72-week data from the Phase 2b ORIGIN clinical trial for IgA Nephropathy (IgAN), showing no loss of kidney function. They are actively enrolling the pivotal Phase 3 ORIGIN 3 study for atacicept, expecting topline data in 1H 2025. The company completed a $287.5 million financing, strengthening their balance sheet and extending cash runway. Key fiscal year 2023 highlights include appointing industry veterans to key positions, presenting positive data from the ORIGIN trial, and advancing their pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
earnings
News
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
Rhea-AI Summary
Vera Therapeutics, Inc. (VERA) will participate in the 44th Annual TD Cowen Health Care Conference. The company's management team will discuss IgAN and hold a Fireside Chat. Investors can access the webcast and a replay of the event on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
conferences
-
News
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Vera Therapeutics, Inc. (VERA) will participate in the 6th Annual Guggenheim Biotechnology Conference in New York on February 7th and 8th. The management team will engage in a fireside chat and be available for one-on-one investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences
-
News
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
Rhea-AI Summary
Vera Therapeutics, Inc. has successfully closed its underwritten public offering of 9,274,194 shares of its Class A common stock, raising approximately $287.5 million. J.P. Morgan, TD Cowen, and Evercore ISI acted as joint book-running managers for the offering, with LifeSci Capital as the lead manager. The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the SEC. The press release emphasizes the final prospectus supplement and accompanying prospectus relating to the offering, which are available for free on the SEC’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
offering
News
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
Rhea-AI Summary
Vera Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its Class A common stock at $31.00 per share, expected to generate approximately $250.0 million in gross proceeds. The offering is expected to close on February 1, 2024, and has the potential for additional shares to be purchased by underwriters. The proposed offering is being made pursuant to a shelf registration statement on Form S-3 and a related registration statement on Form S-3MEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
offering
-
News
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
Rhea-AI Summary
Vera Therapeutics, Inc. plans to commence a public offering to issue and sell $200.0 million of shares of its Class A common stock. The underwriters will have a 30-day option to purchase up to an additional 15% of the shares. The proposed offering is being made pursuant to a shelf registration statement on Form S-3. J.P. Morgan, TD Cowen, and Evercore ISI are acting as joint book-running managers for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.46%
Tags
offering
-
News
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN), showing consistent and sustained reductions in Gd-lgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment. Participants treated with atacicept for 72 weeks demonstrated a 62% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 19%, and a 48% reduction in UPCR in the per-protocol (PP) analysis. Safety data indicated that atacicept was generally well-tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.71%
Tags
clinical trial
News
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) announces the appointment of two industry veterans to lead the development of the company’s drug programs, including its late-stage product candidate, atacicept, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). Dr. Robert M. Brenner, a respected nephrologist and biotechnology executive, is appointed as Chief Medical Officer, while Mr. William D. Turner, with nearly 30 years of drug development and commercialization experience, is appointed as Chief Development Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.74%
Tags
management
Stock VERA logo
Vera Therapeutics, Inc.

Nasdaq:VERA

VERA Rankings

#1747 Ranked by Market Cap
#4564 Ranked by Stock Gains
N/A Ranked by Dividends

VERA Stock Data

2.45B
39.88M
7.95%
85.25%
11.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
BRISBANE

About VERA

trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.